Floatz logo

Abciximab

Brain Ischemia

Centocor, Inc.monoclonal_antibodyPhase 3Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Brain Ischemia cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
City Clinical Hospital No. 67, Moscow, Russia
Phase 4BB
Dipyridamole
UMC Utrecht
Phase 4BB
Sovateltide
Pharmazz, Inc.
Phase 3BB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Asan Medical Center
Phase 4BB
3-N-BUTYLPHTHALIDE
Qianfoshan Hospital
Phase 4BB

View all 36 →

Same molecule, other indications

Abciximab is also rated in:

stroke disorderDormant
CC
Indicative ·
46 / 100
View asset →
acute diseaseDormant
CC
Indicative ·
42 / 100
View asset →
sickle cell diseaseDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →